Insider Selling: STERIS (NYSE:STE) CEO Sells $291,288.00 in Stock

Posted by Brian Himes on Jun 11th, 2026

STERIS plc (NYSE:STE – Get Free Report) CEO Daniel Carestio sold 1,374 shares of STERIS stock in a transaction on Friday, June 5th. The stock was sold at an average price of $212.00, for a total transaction of $291,288.00. Following the completion of the transaction, the chief executive officer directly owned 63,647 shares of the company’s stock, valued at $13,493,164. The trade was a 2.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

STERIS Stock Performance

Shares of NYSE:STE opened at $207.71 on Thursday. STERIS plc has a 52 week low of $195.14 and a 52 week high of $269.44. The stock has a market capitalization of $20.27 billion, a P/E ratio of 26.19 and a beta of 0.93. The firm has a fifty day simple moving average of $216.60 and a two-hundred day simple moving average of $237.99. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25.

STERIS (NYSE:STE – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same period in the previous year, the business earned $2.74 earnings per share. The business’s quarterly revenue was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, analysts expect that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, June 8th. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

Hedge Funds Weigh In On STERIS

A number of large investors have recently made changes to their positions in the company. NewEdge Advisors LLC boosted its stake in shares of STERIS by 2.1% during the 1st quarter. NewEdge Advisors LLC now owns 8,062 shares of the medical equipment provider’s stock worth $1,783,000 after purchasing an additional 168 shares during the period. Glenmede Trust Co. NA boosted its stake in shares of STERIS by 12.2% during the 1st quarter. Glenmede Trust Co. NA now owns 4,120 shares of the medical equipment provider’s stock worth $911,000 after purchasing an additional 447 shares during the period. Segall Bryant & Hamill LLC boosted its stake in shares of STERIS by 5.2% during the 1st quarter. Segall Bryant & Hamill LLC now owns 19,159 shares of the medical equipment provider’s stock worth $4,237,000 after purchasing an additional 940 shares during the period. Groupe la Francaise boosted its stake in shares of STERIS by 9.4% during the 1st quarter. Groupe la Francaise now owns 18,514 shares of the medical equipment provider’s stock worth $4,094,000 after purchasing an additional 1,589 shares during the period. Finally, Western Wealth Management LLC purchased a new position in shares of STERIS during the 1st quarter worth about $25,000. 94.69% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on STE shares. KeyCorp dropped their price objective on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Weiss Ratings cut shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Finally, Piper Sandler reissued an “overweight” rating and issued a $270.00 price objective on shares of STERIS in a research note on Thursday, May 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Check Out Our Latest Analysis on STE

About STERIS

(Get Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.